Seagen Inc (SGEN)

NASDAQ
Currency in USD
Disclaimer
213.70
+7.31(+3.54%)
Closed
After Hours
213.85+0.15(+0.07%)
Unusual trading volume
Day's Range
213.20214.00
52 wk Range
116.08214.00
Prev. Close
206.39
Open
213.8
Day's Range
213.2-214
52 wk Range
116.08-214
Volume
3,162,252
Average Volume (3m)
1,154,088
1-Year Change
53.52%
Shares Outstanding
187,697,935
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
224.83
Upside +5.21%

People Also Watch

110.36
CEG
+0.38%
33.12
KDP
-0.63%
43.16
CPRT
+0.05%
78.06
CSGP
-0.22%
84.93
PCAR
+1.34%

Seagen Inc Company Profile

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Income Statement